Drug Profile
SC 7
Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator University of Washington
- Developer Cell Therapeutics; University of Washington
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Protein-lysine 6-oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Jul 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 13 Jan 1999 Preclinical development for Cancer in USA (Unknown route)